You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Researchers showed, retrospectively, that using a cutoff of 16 circulating DNA mutations they could identify patients who were more likely to respond to immunotherapy.
A Samsung University team found that mutation load measured with the Guardant360 liquid biopsy assay predicted response as well as tissue-based TMB.
The lab will make Lucence's non-invasive cancer tests available to patients in the region, but financial and other terms were not disclosed.
The company will work with researchers at UCSD's Moores Cancer Center on two studies of patients with breast, lung, and colon cancers.
The German drugmaker plans to advance the NSCLC treatment in parallel with tissue-based and liquid biopsy companion assays that can identify best responders.
The Belgian cancer center plans to evaluate Natera's ctDNA assay for evaluating response and detecting minimal residual disease in breast cancer patients.
Quest, the largest private, independent medical laboratory in Singapore, will now be able to offer Lucence's menu of liquid biopsy tests to its patients.
The institutes will explore the use of Inivata's liquid biopsy platform to analyze ctDNA to measure minimal residual disease in NSCLC patients.
The firm said it would likely do a joint submission of its ctDNA assay to the FDA and CMS for approval and a national coverage determination.
Currently marketed for research use by Biofluidica, the test's microfluidic channels use specific cancer antibodies to detect capture circulating tumor cells.